Ursodeoxycholic Acid PCD Pharma Franchise Company
Cafoli Lifecare is a WHO-GMP certified PCD pharma franchise company offering an Ursodeoxycholic Acid (UDCA) range of 8 formulations across tablet, syrup and suspension forms to distributors and franchise partners across India, with district-level monopoly rights on every SKU.
What is Ursodeoxycholic Acid?
Ursodeoxycholic acid is a naturally occurring hydrophilic bile acid used as an oral hepatoprotective and choleretic agent. It works in three linked ways: it reduces the amount of cholesterol secreted into bile, which lets cholesterol gallstones slowly dissolve; it displaces toxic hydrophobic bile acids from the bile acid pool, protecting liver cells from injury in cholestatic disease; and it stimulates bile flow. It is the established first-line therapy for primary biliary cholangitis and is widely used in gallstone and cholestatic liver disease. It is prescription-only. Compound and pharmacology data are available on PubChem.
Ursodeoxycholic Acid Formulations Available with Cafoli Lifecare
The UDCA portfolio comprises 8 formulations across tablet, syrup and suspension presentations. The liquid forms matter clinically — they are what paediatricians and physicians treating elderly patients actually ask for. Composition, packing and net rates are shared on enquiry.
Therapeutic Applications of Ursodeoxycholic Acid
- Primary biliary cholangitis (first-line therapy)
- Dissolution of radiolucent cholesterol gallstones in patients unsuitable for surgery
- Cholestatic liver disease and biliary sludge
- Intrahepatic cholestasis of pregnancy, under obstetric supervision
- Adjunct in non-alcoholic fatty liver disease, at the physician's discretion
Prescribers are gastroenterologists, hepatologists, general physicians, obstetricians and paediatricians.
Why Ursodeoxycholic Acid is a High-Potential Molecule for Distributors
The liver-care segment in India is being reshaped by a single fact: fatty liver has quietly become one of the most commonly diagnosed conditions in the country, carried along by the same obesity and type 2 diabetes epidemic that drives everything else. Every abdominal ultrasound done for another reason turns up another case, and physicians need something to prescribe. UDCA is the safe, familiar, long-established option they reach for, and it is prescribed in months-long courses rather than weeks — so each diagnosis converts into a sustained refill stream rather than a single sale. Add its irreplaceable role in primary biliary cholangitis, its use in gallstone dissolution, and the paediatric and obstetric indications served by our syrup and suspension forms, and an 8-SKU UDCA range gives a distributor a genuinely broad liver-care franchise rather than a single-indication product.
Why Choose Cafoli Lifecare for Your Ursodeoxycholic Acid Franchise
- Monopoly rights — one partner per district, territory protected
- WHO-GMP certified manufacturing and DCGI-approved formulations
- Promotional inputs — visual aids, doctor sample packs, literature, reminder gifts and MR bags
- 1000+ franchise partners across India
- On-time despatch, transparent net rates and dedicated order support
References
- PubChem — Ursodeoxycholic acid compound record, National Library of Medicine
- WHO Model List of Essential Medicines
- PubMed — clinical literature on ursodeoxycholic acid
Our formulations of Ursodeoxycholic Acid find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: